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OBJECTIVES: In this study, we evaluated the association of molecular subtypes, clinical characteristics and
pathological types with the prognosis of patients with medulloblastoma.
METHODS: We analyzed forty patients with medulloblastoma who underwent surgical resection at our center
between January 2004 and June 2014. Risk factors associated with survival, disease progression and recurrence
were analyzed with a univariate Cox regression analysis, and the identified significant risk factors were further
analyzed by Kaplan-Meier survival curves.
RESULTS: Factors associated with overall survival included M stage (p=0.014), calcification (p=0.012),
postoperative treatment, postoperative Karnofsky Performance Scale (KPS) score (p=0.015), and molecular
subtype (p=0.005 for WNT and p=0.008 for SHH). Number of symptoms (p=0.029), M stage (po0.001), and
postoperative radiotherapy (p=0.033) were associated with disease progression. Patients with the WNT or SHH
subtype had better survival outcomes than patients with non-WNT/SHH subtypes. Risk factors for disease
progression-free survival were symptoms 42 and XM1 stage without postoperative radiotherapy. The risk of
recurrence increased with advanced M stage. Protective factors for recurrence included M0 stage and a
combination of chemotherapy and radiotherapy.
CONCLUSION: We identified the risk factors associated with survival, disease progression and recurrence of
medulloblastoma patients. This information is helpful for understanding the prognostic factors related to
medulloblastoma.
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’ INTRODUCTION
Medulloblastoma is a malignant, invasive embryonal
tumor in the cerebellum or fourth ventricle and accounts for
12–25% of all central nervous system tumors. Medullo-
blastoma is the most common malignancy affecting chil-
dren with an annual incidence of five per 100,000 among
children o15 years of age (1). Although surgery remains
the major treatment for medulloblastoma, there is still con-
troversy regarding the impact of resection on the prognosis
of patients with medulloblastoma. Furthermore, in cases
of adherent medulloblastoma to the brainstem, complete
resection is extremely difficult. In addition, metastasis via
the cerebrospinal fluid is common; thus, medulloblastoma
patients often have a poor prognosis and a high mortality
rate (2).
Clinically, the prognosis of patients with medulloblastoma
is often determined according to the pathological type, which
also provides a reference for the application of adjunctive the-
rapies, such as radiotherapy and chemotherapy (3,4). Cur-
rently, the World Health Organization (WHO) classification
system for medulloblastoma is based on histomorphology.
However, patients with the same pathological type of medul-
loblastoma still have distinct genetic backgrounds. Therefore,
the prognosis of patients with medulloblastoma may vary even
within the same WHO pathological type (2).
Recent studies on medulloblastoma have revealed that it is
more accurate to stratify risk based on the molecular pheno-
type, which is also helpful to guide clinical treatment and
determine clinical prognosis (5,6). Currently, medulloblas-
toma is divided into several subtypes according to the
molecular phenotypes: WNT, Sonic hedgehog (SHH) and non-
SHH/WNT (7,8). In addition, Ellison et al. (2) differentiated
medulloblastoma subtypes by immunohistochemistry, and
the authors validated their findings using microarray anal-
yses. Ellison et al. found that it is feasible to differentiate
different subtypes of medulloblastoma by immunohisto-
chemistry (2). In the present study, the molecular phenotyp-
ing methods for medulloblastoma reported by Ellison et al.
(2) were utilized to detect the expression of Yes associatedDOI: 10.6061/clinics/2017(05)07
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protein 1 (YAP1) and GRB2-associated protein 1 (GAB1) by
immunohistochemistry.
YAP1 is an auxiliary initiator of oncogene transcription
and can promote cellular proliferation and transformation
(9). Gene expression profiling of medulloblastoma reveals
that it is highly expressed in the WNT and SHH subtypes
of medulloblastoma and is not observed in the other two
medulloblastoma subtypes (9,10). In contrast, GAB1 belongs
to the Gab family and has specificity in the SHH signaling
pathway of medulloblastoma cells (2). In the present study,
YAP1 protein served as a specific marker of the WNT and
SHH medulloblastoma subtypes while GAB1 was used as a
specific marker of the SHH medulloblastoma subtype.
In this retrospective observational study, we evaluated
the association of molecular subtypes, clinical characteristics
and pathological types with the prognosis of patients with
medulloblastoma. The primary outcome was overall survival
(OS). Risk factors associated with survival, disease progres-
sion and recurrence were analyzed with a univariate Cox
regression analysis, and the identified significant risk factors
were further analyzed via Kaplan-Meier survival curves.
YAP1 served as a specific marker of the WNT and SHH sub-
types; GAB1 served as a specific marker of the SHH subtype.
This analysis may provide information pertinent to treatment
decisions for patients with medulloblastoma.
’ MATERIALS AND METHODS
Study design
In this retrospective analysis, we reviewed the medical
records of 40 children with pathologically proven medullo-
blastoma who underwent surgical resection at the Affiliated
Children’s Hospital of Fudan University between January
2004 and June 2014. Medulloblastoma was diagnosed and
classified into the following subtypes according to the 2016
WHO classification system of central nervous system tumors
(11): classic subtype, desmoplastic/nodular subtype, exten-
sive nodularity subtype or large cell/anaplastic subtype.
Inclusion criteria included the following: absence of ano-
ther severe disease diagnosis, a complete medical record
with followed-up data, and medulloblastoma tissues that
were fixed in 10% neutral formalin and embedded in
paraffin following resection. All deaths were a result of
disease progression or recurrence; however, one patient
who died within 3 days after surgery was excluded. Two
other patients were excluded due to a lack of follow-up
data. This study was approved by the institutional review
board of Fudan University.
Radiotherapy and chemotherapy protocols
After 28 days following the resection procedure, patients
underwent postoperative craniospinal irradiation (CSI)
delivering a median craniospinal dose of 36 Gy with addi-
tional boosts to the posterior fossa up to 54.0–55.8 Gy weekly
for 8 weeks. Chemotherapy was initiated 6 weeks after radio-
therapy in eight 6-week courses consisting of 4 weeks of che-
motherapy followed by 2 weeks of rest. Specifically, patients
received an intravenous infusion of cisplatin (75 mg/m2) on
Day 0; intravenous bolus infusion of vincristine (1.5 mg/m2,
max of 2 mg/dose) on Days 1, 7, and 14; and intravenous
infusion of cyclophosphamide (1,000 mg/m2) on Days 21
and 22. Examinations of the patients’ skulls and spines by
MRI were performed once every 12 weeks.
Survival analysis
The OS time was defined as the time interval between
surgery and death or the last follow-up and was expressed
in months. The disease progression-free survival (PFS) dura-
tion was defined as the time interval between date of surgery
and date of progression-free, last follow-up, or death. The
recurrence-free duration was calculated from the date of
surgery to the date of recurrence, last follow-up, or death.
Censored data were considered if the patient survived at the
last follow-up and was marked in the survival curve.
Karnofsky performance scale
Postoperative Karnofsky performance scale (KPS) scores
were determined for all patients during hospitalization. In
this scale, a score of 100 indicates that the physical condition
of the patient is normal without evidence of disease, while a
score of 10 indicates rapid, fatal disease progression.
Immunohistochemistry
Immunochemistry analysis of YAP1 and GAB1 expression
was performed as previously described (2). After surgical
resection, medulloblastoma tissues were fixed in 4% neutral
formalin and embedded in paraffin. The paraffin-embedded
tissues provided by the Department of Pathology in the
Affiliated Children’s Hospital of Fudan University were cut
into 4-mm sections. After routine processing with xylene,
graded ethanol solutions, and 3% H2O2 for 10 min, antigen
retrieval was performed in 0.05 M citrate buffer (pH=6.0) at
100oC for 5–10 min followed by blocking in goat serum for
10 min. Immunohistochemistry analyses were performed
using a EnVision two-step immunohistochemistry system
(DAKO, Kyoto, Japan) with anti-GAB1 polyclonal antibodies
(1:50, Abcam; Cambridge, MA, USA) and anti-YAP1 poly-
clonal antibodies (1:50, Abcam) for 1 h at 37oC. After washing,
sections were incubated in HRP-conjugated goat anti-rabbit
IgG (H+L; Jackson ImmunoResearch; West Grove, PA, USA)
for 1 h at 37oC. Visualization was performed with DAB.
The immunohistochemistry results were semi-quantified.
Five fields were randomly selected from each section at a
magnification of 200 , and the positive cells were counted
and averaged. Cells positive for YAP1 exhibited brown
granules in the nucleus and cytoplasm; GAB1-positive cells
exhibited granules in the nucleus. Positive cells were counted
to obtain an average. Sections undergoing hematoxylin and
eosin (HE) staining also served as controls. At a magnifica-
tion of 400 , the proportion of positive cells X30% at
the strong positive area was regarded as positive (+) while
the proportion of positive cells o30% was regarded as
negative (-).
Statistical analysis
All data were presented as frequencies and percentages
and were assessed with a Chi-squared test. A Cox propor-
tional hazard model was performed to identify effectors of
poor survival outcome. To quantify the strength of the
association between a potential risk factor and death, disease
progression, or medulloblastoma recurrence, hazard ratios
(HR) and 95% confidence intervals (CI) were estimated and
reported. Given the limited sample size, only significant
variables with p-valueso0.01 in the univariate analysis were
used for further multivariable analyses. If both postopera-
tive radiotherapy and postoperative chemotherapy met the
criterion, the variable ‘‘both postoperative radiotherapy and
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chemotherapy’’ was used instead. In cases where no variable
with p-valueso0.01 was identified in the univariate analysis,
a multivariable analysis was not performed. A p-value o0.05
was considered significant. All statistical analyses were two-
sided and performed using IBM SPSS statistics for Windows
version 22.0 (IBM Corp., Armonk, NY, USA).
’ RESULTS
Patient demographics
Patient characteristics are summarized in Table 1. Patients
with partial or complete resection exhibited similarities in
most characteristics except a higher percentage of patients
with partial resection received radiotherapy after surgery
than did patients with complete resection (100% vs. 50%,
p=0.022). Among the 40 patients, most were males (n=29,
72.5%) and X3 years of age (n=29, 72.5%). Clinical features
of central medulloblastoma (n=36, 90%), complete tumor
resection (n=34, 85%) and classic subtype (n=33, 82.5%) were
commonly observed among the patients. Other subtypes
included the desmoplastic/nodular (D) subtype in 3% (n=1)
and the large cell/anaplastic (LC/A) subtype in 15% (n=6).
At least 80% of the patients presented with an M stage at M0
and Tstage at T3 or above (Table 1). Calcification (n=14) or pre-
operative cerebral tonsillar herniation (n=9) was observed in
23%–35% of patients. Whereas 57.5% of patients (n=23) recei-
ved radiotherapy, only 35% (n=14) were treated with che-
motherapy after surgery. The postoperative KPS score wasX80
in 80% of the patients (n=32), suggesting near to normal
activity and either the absence of disease signs/symptoms or
the presence of only mild disease signs/symptoms.
Molecular subtype analysis
The medulloblastoma subtypes were identified using YAP1
and GAB1 immunohistochemistry analyses. Supplementary
Figure S1 shows representative images of the WNT, SHH, and
Table 1 - Characteristics of the medulloblastoma patients (n=40).
Variables Classification Partial resection (n=6) Complete resection (n=34) p
Characteristics
Age, y o 3 1 (16.7) 10 (29.4) 0.519
X 3 5 (83.3) 24 (70.6)
Sex Female 3 (50) 8 (23.5) 0.181
Male 3 (50) 26 (76.5)
Clinical features
Tumor site Central 1 (16.7) 3 (8.8) 0.555
Peripheral 5 (83.3) 31 (91.2)
Number of symptoms p 2 2 (33.3) 20 (58.8) 0.247
4 2 4 (66.7) 14 (41.2)
Tumor connecting to brainstem No 3 (50) 17 (50) 0.999
Yes 3 (50) 17 (50)
Ventriculo-peritoneal shunt No 3 (50) 18 (52.9) 0.894
Yes 3 (50) 16 (47.1)
Histological type Classic 5 (83.3) 28 (82.4) 0.954
Large cell or desmoplastic 1 (16.7) 6 (17.6)
M stage M0 5 (83.3) 30 (88.2) 0.738
X M1 1 (16.7) 4 (11.8)
T stage T1-2 1 (16.7) 7 (20.6) 0.825
T3-4 5 (83.3) 27 (79.4)
Cystic-solid node No 3 (50) 20 (58.8) 0.687
Yes 3 (50) 14 (41.2)
Calcification No 3 (50) 23 (67.6) 0.403
Yes 3 (50) 11 (32.4)
Cerebrospinal fluid fistula No 5 (83.3) 26 (76.5) 0.711
Yes 1 (16.7) 8 (23.5)
Cerebral herniation No 6 (100) 26 (76.5) 0.184
Yes 0 (0) 8 (23.5)
Postoperative radiotherapy No 0 (0) 17 (50) 0.022
Yes 6 (100) 17 (50)
Postoperative chemotherapy No 4 (66.7) 22 (64.7) 0.926
Yes 2 (33.3) 12 (35.3)
Both radiotherapy and chemotherapy None or singly therapy only 4 (66.7) 27 (79.4) 0.491
Both therapies 2 (33.3) 7 (20.6)
Postoperative KPS score o 80 0 (0) 8 (23.5) 0.184
X 80 6 (100) 26 (76.5)
Molecular subtype WNT 0 (0) 8 (23.5) 0.352
SHH 3 (50) 10 (29.4)
Non-SHH / WNT 3 (50) 16 (47.1)
Long-term outcome
Disease progression No 2 (33.3) 16 (47.1) 0.533
Yes 4 (66.7) 18 (52.9)
Recurrence No 1 (16.7) 19 (55.9) 0.077
Yes 5 (83.3) 15 (44.1)
Death No 1 (16.7) 12 (35.3) 0.369
Yes 5 (83.3) 22 (64.7)
Abbreviations: KPS, Karnofsky Performance Scale; SHH, sonic hedge hog.
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non-SHH/WNT subtypes. As shown in Table 1, 20% of the
tumors (n=8) were the WNT subtype, and 32.5% (n=13) were
the SHH subtype. The remaining 47.5% of patients (n=19)
presented with the non-SHH/WNT subtype of medullo-
blastoma.
Univariate and multivariable analyses of predictors
of poor OS
As shown in Table 1, 32.5% of the children survived to
the last follow-up. The factors associated with the OS
of medulloblastoma patients are shown in Table 2. The
univariate analysis indicated that patients with M1 stage
(HR=3.63, 95% CI: 1.30–10.09, p=0.014) or calcification
(HR=3.10, 95% CI: 1.28–7.53, p=0.012) were at significantly
greater risk of death.
Treatment with radiotherapy, chemotherapy, or both fol-
lowing surgical resection positively impacted patient sur-
vival. The HRs were 0.34 (95% CI: 0.1–0.74, p=0.007) for
radiotherapy, 0.19 (95% CI: 0.06–0.59, p=0.004) for che-
motherapy, and 0.28 (95% CI: 0.10–0.79, p=0.017) for both
therapies. A postoperative KPS score X80 was also asso-
ciated with a lower risk of death (HR=0.31, 95% CI: 0.12–
0.80, p=0.015). Relative to patients with non-SHH/WNT
tumors, patients with the WNT (HR=0.16, 95% CI: 0.05–0.58,
Supplementary Figure S1 - Immunohistochemical analyses of YAP and GAB1 to identify medulloblastoma subtypes. (A, B) The SHH
subtype was positive for both (A) YAP1 and (B) GAB1. (C, D) TheWNT subtype was positive for (C) YAP1 and negative for (D) GAB1. (E, F)
The non-SHH/WNT subtype was negative for both YAP1 and GAB1. Magnification, 400 ; scale bar, 50 mm.
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p=0.005) or SHH (HR= 0.29, 95% CI: 0.12–0.73, p=0.008) sub-
types were less likely to have a poor outcome.
In the multivariable analysis, the effect of the SHH mole-
cular subtype disappeared (Table 2). Postoperative treatment
with both radiotherapy and chemotherapy (HR=0.16, 95% CI:
0.04–0.66, p=0.011) and the WNTmolecular subtype (HR=0.10,
95% CI: 0.02–0.43, p=0.002) continued to be associated with
better survival outcomes (Table 2).
Table 2 - Univariate Cox proportional hazard model of factors associated with poor survival.
Variables HR (95% CI) p-value
Age, y
o 3 Reference
X 3 0.67 (0.30, 1.52) 0.342
Sex
Female Reference
Male 0.95 (0.41, 2.20) 0.914
Tumor site
Peripheral Reference
Central 0.78 (0.23, 2.63) 0.684
Number of symptoms
p 2 Reference
4 2 2.17 (1.00, 4.72) 0.051
Tumor connecting to brainstem
No Reference
Yes 1.11 (0.51, 2.44) 0.791
Ventriculo-peritoneal shunt
No Reference
Yes 0.92 (0.43, 1.98) 0.837
Tumor resection
Partial Reference
Complete 0.84 (0.31, 2.26) 0.735
Histological type
Classic Reference
Large cell or desmoplastic 1.25 (0.46, 3.39) 0.656
M stage
M0 Reference
X M1 3.63 (1.30, 10.09) 0.014
T stage
T3-4 Reference
T1-2 0.90 (0.36, 2.26) 0.825
Cystic-solid node
No Reference
Yes 1.33 (0.62, 2.88) 0.462
Calcification
No Reference
Yes 3.10 (1.28, 7.53) 0.012
Cerebrospinal fluid fistula
No Reference
Yes 2.61 (1.03, 6.65) 0.044
Cerebral herniation
No Reference
Yes 0.67 (0.25, 1.78) 0.423
Postoperative radiotherapy
No Reference
Yes 0.34 (0.16, 0.74) 0.007
Postoperative chemotherapy
No Reference
Yes 0.19 (0.06, 0.59) 0.004
Both radiotherapy and chemotherapy
None or singly therapy only Reference
Both therapies 0.28 (0.10, 0.79) 0.017
Postoperative KPS score
o 80 Reference
X 80 0.31 (0.12, 0.8) 0.015
Molecular subtype
Non-SHH / WNT Reference
WNT 0.16 (0.05, 0.58) 0.005
SHH 0.29 (0.12, 0.73) 0.008
Recurrence 0.040
No Reference
Yes 2.49 (1.07, 40.80)
Bold values indicate statistical significance, p o 0.05.
Abbreviations: HR, hazard ratio; CI, confidence interval; KPS, Karnofsky Performance Scale; SHH, sonic hedge hog.
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Kaplan-Meier survival analysis
The Kaplan-Meier curves displaying factors associated
with OS are shown in Figure 1. Four of five patients with M1
stage or above died within 6 months after surgery, with OS
rates of 20% at 6 months and 0% at 20 months (Figure 1A).
OS rates among patients with M0 stage were 61.8% at 1 year,
54.1% at 2 years, 20.3% at 3 years, and 6.8% after 44 months
(Figure 1A). Eleven of 14 patients with calcification died
within 13 months after surgery (OS rates of 35.7% at 6
months and 14.3% after 20 months) (Figure 1B). OS rates in
Figure 1 - Kaplan-Meier curves of overall survival according to (A) M stage, (B) calcification, (C) postoperative radiotherapy, (D)
postoperative chemotherapy, (E) postoperative adjuvant therapy, (F) postoperative KPS score, and (G) molecular subtype. A log-rank
test was performed to test the survival status between groups.
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patients without calcification were 67.5% at 1 year, 61.8% at 2
years, 23.2% at 3 years, and 7.7% after 44 months (Figure 1B).
The OS rate among patients not receiving radiotherapy
was 23.5% at 1 year and 8.8% after 27 months versus 82.6% at
1 year, 56.5% at 27 months, and 0% at 44 months among
patients receiving radiotherapy (Figure 1C). OS rates among
patients not treated with chemotherapy were 42.3% at 1 year,
24.7% at 2 years and 0% at 27 months, compared to 83.6% at
1 year, 74.3% at 2 years, 31.8% at 3 years and 10.6% after 44
months among patients treated with chemotherapy (Figure 1D).
The OS rate among patients receiving both chemotherapy
and radiotherapy were 100% at 2 years and 40% at 3 years
versus 44.4% at 1 year and 29.0% at 2 years among patients
without chemotherapy and radiotherapy (Figure 1E).
Seven of eight patients with postoperative KPS o80 died
within one year after surgery (OS rates were 50% at 6 months
and 12.5% after 12 months). In contrast, patients with posto-
perative KPS scores of X80 exhibited OS rates of 68.8%
at 1 year, 54.1% at 2 years, 20.3% at 3 years, and 6.8% after
44 months (Figure 1F). The 1-year, 2-year, 3-year and ter-
minal OS rates were 85.7%, 64.3%, and 32.1% among patients
with the WNT subtype, respectively; 84.6%, 72.5%, 18.1%
and 0% among patients with the SHH subtype, respectively;
and 26.3%, 19.7%, 9.9% and 0% among patients with the
non-SHH/WNT subtypes, respectively (Figure 1G).
Univariate analysis of potential predictors of
disease progression
As shown in Table 3, the number of symptoms (e.g., head-
ache, vomiting, ataxia, nystagmus, cranial nerve palsy, increa-
sed head circumference, hernia, and secondary epilepsy), M
stage, and postoperative radiotherapy were associated with
disease progression. Patients withX2 symptoms had 2.61-fold
higher risk of disease progression (95% CI: 1.10–6.19, p=0.029).
In addition, patients with M1 stage or above had 20.76 times
(95% CI: 3.77–114.29, po0.001) higher risk of disease pro-
gression. Finally, postoperative radiotherapy was protective
against disease progression (HR=0.39; 95% CI: 0.16–0.93,
p=0.033).
Univariate analysis of potential predictors of
recurrence
The univariate analysis indicated that recurrence was
associated with a higher risk of death (HR=2.49, 95% CI:
1.07–40.80, p=0.040; Table 2); the 1- and 3-year OS rates of
patients without recurrence were 70% and 42%, compared to
43.7% and 0% among patients with recurrence. We next
determined which factors were associated with recurrence
via a univariate analysis. As shown in Table 4, the risk of
recurrence increased with advanced M stage (HR=30.71; 95%
CI: 3.92–240.44, p=0.001). In contrast, patients receiving both
chemotherapy and radiotherapy were less likely to experi-
ence recurrence than patients with only one therapy or with-
out either radiotherapy or chemotherapy (HR=0.21, 95%
CI: 0.05–0.93, p=0.040).
’ DISCUSSION
In this retrospective analysis, we identified the clinical
characteristics, including molecular subtypes, and treatment
outcomes associated with the prognosis of pediatric patients
with medulloblastoma in China. M stage, calcification, posto-
perative treatment (radiotherapy, chemotherapy, and both),
postoperative KPS score, and molecular subtype were all
associated with the OS of medulloblastoma patients. Factors
associated with disease progression included number of
symptoms, M stage and postoperative radiotherapy. M stage
and postoperative radiotherapy or chemotherapy were asso-
ciated with recurrence. Considered together, molecular subtyp-
ing of medulloblastoma was more predictive of survival than
histopathology in patients undergoing adjuvant therapy.
This is the first study to report the clinical features, prog-
noses, and risk factors of patients with pediatric medullo-
blastoma among a Chinese Han population. As a single-center
study in China, this report has inherent, unique ethnic
characteristics, which could be regarded as important sup-
plementary information for global studies regarding pedia-
tric medulloblastoma. In addition, this is the first study to
compare the prognosis obtained using molecular typing
compared to pathological classification in a single-center
study. Specifically, this study highlights the advantages of
molecular typing, which provides a more intuitive and relia-
ble indicator of molecular classification for prognosis than
pathological classification.
In the present study, no differences among patient out-
comes were detected between the pathological types. Because
the prognosis of patients with the same pathological type of
medulloblastoma can be drastically different due to varying
genetic backgrounds (12), the development of new molecular
subtyping of medulloblastoma is necessary. In the present
study, molecular subtyping analyses revealed that almost half
of the children presented with the non-SHH/WNT subtype.
Furthermore, our univariate and multivariable analyses both
indicated that the prognoses of patients with the WNT sub-
type was the best followed by the SHH subtype of medul-
loblastoma. These findings are consistent with another study
of medulloblastoma in China (13). Our results further confir-
med the prognostic superiority of determining molecular
subtypes over pathological types. However, the molecular
subtypes (as determined by YAP1 and GAB1) were not
associated with disease recurrence or progression. Therefore,
further studies are required to identify additional markers,
such as glutamate (a predictive marker for patient survival for
pediatric medulloblastoma (14)), to improve molecular sub-
typing of medulloblastoma among children. In addition, con-
sensus regarding the method for identifying medulloblastoma
subtypes (e.g., immunohistochemistry, CTNNB1 mutation
analysis, or quantitative PCR) (15) should be reached through
additional studies. Finally, larger studies will permit the patients
to be further divided into those having Group 3 and Group 4
tumors in order to more completely subtype the tumors and
their prognostic impact.
In the present study, disease progression was associated
with the presence of 42 symptoms, which might be related
to the special location of medulloblastoma in children. Medul-
loblastoma is usually present in the midline of the posterior
fossa and may cause disordered cerebrospinal fluid circulation
resulting in cerebellar dysfunction characterized by intracra-
nial hypertension and cerebellar tissue destruction (16). The
clinical symptoms mainly include headache, vomiting, ataxia,
nystagmus, cranial nerve palsy, an increase in head circum-
ference, cerebral hernia and secondary epilepsy. Nervous
system injury caused by the cancer or cerebral hernia due to
intracranial hypertension can directly threaten the life of the
patient. Previous studies have confirmed that the time interval
between disease onset and surgery may directly affect the
prognosis of a patient with medulloblastoma (17), which may
be related to greater symptom severity.
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The staging for medulloblastoma is mainly based on the
Chang staging system, which is based on the pre-operative
imaging and intra-operative findings to determine M stage
and T stage. M stage is better for assessing the prognosis
of children with medulloblastoma than T stage (1,15), which
is consistent with the present study in which OS as well
as disease progression and recurrence were significantly
associated with M stage (M0 vs. XM1). However, no such
associations were observed with T stage (T1-2 vs. T3-4).
The postoperative KPS score has also been used in the
determination of postoperative prognosis. In the present
study, postoperative KPS scores X80 were associated with
significantly longer OS. In addition to the KPS score, OS
was also associated with tumor calcification that could be
Table 3 - Univariate Cox proportional hazard model of factors associated with disease progression.
Variables HR (95% CI) p-value
Age, y
o 3 Reference
X 3 0.63 (0.26, 1.51) 0.299
Sex
Female Reference
Male 0.74 (0.29, 1.90) 0.528
Tumor site
Peripheral Reference
Central 0.68 (0.20, 2.32) 0.542
Number of symptoms
p 2 Reference
4 2 2.61 (1.10, 6.19) 0.029
Tumor connecting to brainstem
No Reference
Yes 1.88 (0.79, 4.48) 0.157
Ventriculo-peritoneal shunt
No Reference
Yes 1.58 (0.66, 3.77) 0.308
Level of tumor section
Subtotal Reference
Total 0.84 (0.28, 2.51) 0.749
Histological type
Classic Reference
Large cell or desmoplastic 1.15 (0.39, 3.40) 0.805
M stage
M0 Reference
X M1 20.76 (3.77, 114.29) o0.001
T stage
T3-4 Reference
T1-2 2.21 (0.85, 5.73) 0.104
Cystic-solid node
No Reference
Yes 1.50 (0.65, 3.47) 0.347
Calcification
No Reference
Yes 2.23 (0.93, 5.36) 0.074
Cerebrospinal fluid fistula
No Reference
Yes 2.45 (0.98, 6.12) 0.055
Cerebral herniation
No Reference
Yes 0.62 (0.21, 1.84) 0.392
Postoperative radiotherapy
No Reference
Yes 0.39 (0.16, 0.93) 0.033
Postoperative chemotherapy
No Reference
Yes 0.45 (0.18, 1.15) 0.094
Both radiotherapy and chemotherapy
No Reference
Yes 3.38 (0.98, 11.65) 0.054
Postoperative KPS score
o 80 Reference
X 80 0.45 (0.17, 1.18) 0.104
Molecular subtype
Non-SHH / WNT Reference
WNT 0.46 (0.15, 1.44) 0.183
SHH 0.40 (0.15, 1.09) 0.074
Bold values indicate statistical significance, p o 0.05.
Abbreviations: HR, hazard ratio; CI, confidence interval; KPS, Karnofsky Performance Scale; SHH, sonic hedge hog.
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visualized with an imaging examination. Our univariate
and multivariable analyses both indicated that patients
receiving postoperative radiotherapy or chemotherapy exhi-
bited significantly better OS rates than patients not receiv-
ing postoperative radiotherapy or chemotherapy, which is
consistent with previous studies (12,13). Given the toxicity of
radiotherapy and chemotherapy to the nervous system in
children (18), in depth studies are necessary to examine
individualized therapies according to the risk stratification
of medulloblastoma patients. For example, the dose of
radiation or chemotherapeutics may be reduced in children
with a low risk for recurrence, which may minimize the
associated toxicity without compromising the therapeutic
effectiveness.
Table 4 - Univariate Cox proportional hazard model of factors associated with medulloblastoma recurrence.
Variables HR (95% CI) p-value
Age, y
o 3 Reference
X 3 0.54 (0.22, 1.32) 0.178
Gender
Female Reference
Male 0.51 (0.2, 1.29) 0.155
Tumor site
Peripheral Reference
Central 0.97 (0.22, 4.22) 0.970
Number of symptoms
p 2 Reference
4 2 2.27 (0.93, 5.55) 0.073
Tumor connecting to brainstem
No Reference
Yes 2.05 (0.81, 5.14) 0.128
Ventriculo-peritoneal shunt
No Reference
Yes 1.6 (0.64, 4.01) 0.317
Level of tumor section
Subtotal Reference
Total 0.54 (0.19, 1.52) 0.243
Histological type
Classic Reference
Large cell or desmoplastic 1.26 (0.42, 3.78) 0.679
M stage
M0 Reference
X M1 30.71 (3.92, 240.44) 0.001
T stage
T3-4 Reference
T1-2 1.48 (0.49, 4.48) 0.492
Cystic-solid node
No Reference
Yes 1.22 (0.5, 2.95) 0.666
Calcification
No Reference
Yes 2.17 (0.86, 5.48) 0.100
Cerebrospinal fluid fistula
No Reference
Yes 2.28 (0.86, 6.04) 0.098
Cerebral herniation
No Reference
Yes 0.68 (0.23, 2.04) 0.489
Postoperative radiotherapy
No Reference
Yes 0.60 (0.24, 1.47) 0.261
Postoperative chemotherapy
No Reference
Yes 0.41 (0.16, 1.11) 0.079
Both radiotherapy and chemotherapy
No Reference
Yes 0.21 (0.05, 0.93) 0.040
Postoperative KPS score
o 80 Reference
X 80 0.68 (0.22, 2.06) 0.492
Molecular subtype
Non-SHH / WNT Reference
WNT 0.61 (0.18, 2.01) 0.417
SHH 0.64 (0.23, 1.74) 0.379
Bold values indicate statistical significance, p o0.05.
Abbreviations: HR, hazard ratio; CI, confidence interval; KPS, Karnofsky Performance Scale; SHH, sonic hedge hog.
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An age of o3 years has been identified as a factor asso-
ciated with poor prognosis in medulloblastoma patients (19).
However, no such association was observed in the pre-
sent study. In addition, previous studies have shown that
the extent of resection was a key factor affecting the prog-
nosis of medulloblastoma patients (20,21). Pogorzala et al.
(22) reported that incomplete surgical resection was asso-
ciated with poor outcomes. However, OS times were similar
in children with total resection and in those with subtotal
resection. Furthermore, OS time was comparable between
patients with and without tumors that were adherent to the
brainstem. Although these differences may be due to the
small sample size in the present study, we speculate that total
resection should not be performed if it is difficult to com-
pletely remove the cancer, especially given the evidence
showing that the residual cancer cells will be cleared by
postoperative radiotherapy (23).
This study is limited in that the results are from a single
institution and the study size was small, which was due in
part due to patients not seeking therapy as a result of a poor
prognosis or financial burden. In addition, the neurosurgical
department at our hospital is relatively new. Thus, the results
need to be confirmed with larger sample sizes. In addition,
the precise types of chemotherapy and radiotherapy and
their influence on patient prognosis were not determined.
Moreover, only 35% of the patients were treated with chemo-
therapy, and 57.5% of the patients were treated with radio-
therapy, which was due, in part, to the large proportion of
patients under 3 years of age (27.5%). However, this factor
may have affected the OS rate, which was only 32.5%.
Finally, limitations regarding the immunohistochemistry
method utilized for subtype classification did not permit
the separation of medulloblastoma groups 3 and 4 molecular,
which could be identified via mRNA analysis (24). Therefore,
differences between the subtypes would not have been
identified.
Molecular subtypes are better determinants of the prog-
noses of medulloblastoma patients than pathological types,
which may be used to guide the therapy of medulloblas-
toma. Further studies are necessary to validate our results
with a larger sample size and to identify and improve the
novel markers of different medulloblastoma subtypes to
make this approach more reliable.
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